Sulfiredoxin : a potential therapeutic agent? : Antioxidants in the Prevention of Human Diseases
Identifieur interne : 000778 ( PascalFrancis/Curation ); précédent : 000777; suivant : 000779Sulfiredoxin : a potential therapeutic agent? : Antioxidants in the Prevention of Human Diseases
Auteurs : Victoria J. Findlay [États-Unis] ; Haim Tapiero [France] ; Danyelle M. Townsend [États-Unis]Source :
- Biomedicine & pharmacotherapy [ 0753-3322 ] ; 2005.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The importance of antioxidants in maintaining homeostasis has long been accepted and includes antioxidant proteins such as, peroxire-doxin (Prx), superoxide dismutase and glutathione S transferases. Sulfiredoxin (Srx) is a recently identified antioxidant protein with a role in signaling through catalytic reduction ofoxidative modifications. It was first characterized for its regulation of Prx(s) through reduction of the conserved cysteine from sulfinic to sulfenic acid, thereby impacting the role of Prx in regulation of downstream transcription factors and kinase signaling pathways. Furthermore, the reduction of sulfinic to sulfenic acid prevents further oxidation of the conserved cysteine residue to sulfonic acid, the end result of which is degradation. Srx also has a role in the reduction of glutathionylation a post-translational, oxidative modification that occurs on numerous proteins and has been implicated in a wide variety of pathologies, including Parkinson's disease. The regulation of glutathionylation/deglutathionylation (or thiol switch) has been likened to phosphorylation/dephosphorylation, another post-translational modification involved in the regulation of signaling pathways. Unlike, the reduction of Prx over-oxidation, Srx-dependent deglutathionylation appears to be non-specific. Deglutathionylation of multiple proteins has been observed both in vitro and in vivo in response to oxidative and/or nitrosative stress. This review discusses Srx as a novel antioxidant, and focuses on its potential role in the regulation of glutathionylation/deglutathionylation pathways, that have been implicated in a growing number of disease states.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C56
Links to Exploration step
Pascal:05-0388191Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sulfiredoxin : a potential therapeutic agent? : Antioxidants in the Prevention of Human Diseases</title><author><name sortKey="Findlay, Victoria J" sort="Findlay, Victoria J" uniqKey="Findlay V" first="Victoria J." last="Findlay">Victoria J. Findlay</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Cell and Molecular Pharmacology, Medical University of South Carolina</s1><s2>Charleston, SC 29425</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Tapiero, Haim" sort="Tapiero, Haim" uniqKey="Tapiero H" first="Haim" last="Tapiero">Haim Tapiero</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Université de Paris, Faculté de pharmacie, CNRS UMR 8612, 5, rue Jean -Baptisle-Clément</s1><s2>94200 Chatenay-Malabry</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Townsend, Danyelle M" sort="Townsend, Danyelle M" uniqKey="Townsend D" first="Danyelle M." last="Townsend">Danyelle M. Townsend</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Sciences. Medical University of South Carolina</s1><s2>Charleston, SC 29425</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0388191</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0388191 INIST</idno><idno type="RBID">Pascal:05-0388191</idno><idno type="wicri:Area/PascalFrancis/Corpus">000C56</idno><idno type="wicri:Area/PascalFrancis/Curation">000778</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sulfiredoxin : a potential therapeutic agent? : Antioxidants in the Prevention of Human Diseases</title><author><name sortKey="Findlay, Victoria J" sort="Findlay, Victoria J" uniqKey="Findlay V" first="Victoria J." last="Findlay">Victoria J. Findlay</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Cell and Molecular Pharmacology, Medical University of South Carolina</s1><s2>Charleston, SC 29425</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Tapiero, Haim" sort="Tapiero, Haim" uniqKey="Tapiero H" first="Haim" last="Tapiero">Haim Tapiero</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Université de Paris, Faculté de pharmacie, CNRS UMR 8612, 5, rue Jean -Baptisle-Clément</s1><s2>94200 Chatenay-Malabry</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Townsend, Danyelle M" sort="Townsend, Danyelle M" uniqKey="Townsend D" first="Danyelle M." last="Townsend">Danyelle M. Townsend</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Sciences. Medical University of South Carolina</s1><s2>Charleston, SC 29425</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></analytic><series><title level="j" type="main">Biomedicine & pharmacotherapy</title><title level="j" type="abbreviated">Biomed. pharmacother.</title><idno type="ISSN">0753-3322</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Biomedicine & pharmacotherapy</title><title level="j" type="abbreviated">Biomed. pharmacother.</title><idno type="ISSN">0753-3322</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Glutathione</term><term>Oxidative stress</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term><term>Glutathion</term><term>Stress oxydatif</term><term>Oxygène actif</term><term>Azote actif</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The importance of antioxidants in maintaining homeostasis has long been accepted and includes antioxidant proteins such as, peroxire-doxin (Prx), superoxide dismutase and glutathione S transferases. Sulfiredoxin (Srx) is a recently identified antioxidant protein with a role in signaling through catalytic reduction ofoxidative modifications. It was first characterized for its regulation of Prx(s) through reduction of the conserved cysteine from sulfinic to sulfenic acid, thereby impacting the role of Prx in regulation of downstream transcription factors and kinase signaling pathways. Furthermore, the reduction of sulfinic to sulfenic acid prevents further oxidation of the conserved cysteine residue to sulfonic acid, the end result of which is degradation. Srx also has a role in the reduction of glutathionylation a post-translational, oxidative modification that occurs on numerous proteins and has been implicated in a wide variety of pathologies, including Parkinson's disease. The regulation of glutathionylation/deglutathionylation (or thiol switch) has been likened to phosphorylation/dephosphorylation, another post-translational modification involved in the regulation of signaling pathways. Unlike, the reduction of Prx over-oxidation, Srx-dependent deglutathionylation appears to be non-specific. Deglutathionylation of multiple proteins has been observed both in vitro and in vivo in response to oxidative and/or nitrosative stress. This review discusses Srx as a novel antioxidant, and focuses on its potential role in the regulation of glutathionylation/deglutathionylation pathways, that have been implicated in a growing number of disease states.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0753-3322</s0></fA01><fA02 i1="01"><s0>BIPHEX</s0></fA02><fA03 i2="1"><s0>Biomed. pharmacother.</s0></fA03><fA05><s2>59</s2></fA05><fA06><s2>7</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Sulfiredoxin : a potential therapeutic agent? : Antioxidants in the Prevention of Human Diseases</s1></fA08><fA11 i1="01" i2="1"><s1>FINDLAY (Victoria J.)</s1></fA11><fA11 i1="02" i2="1"><s1>TAPIERO (Haim)</s1></fA11><fA11 i1="03" i2="1"><s1>TOWNSEND (Danyelle M.)</s1></fA11><fA14 i1="01"><s1>Department of Cell and Molecular Pharmacology, Medical University of South Carolina</s1><s2>Charleston, SC 29425</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Université de Paris, Faculté de pharmacie, CNRS UMR 8612, 5, rue Jean -Baptisle-Clément</s1><s2>94200 Chatenay-Malabry</s2><s3>FRA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Pharmaceutical Sciences. Medical University of South Carolina</s1><s2>Charleston, SC 29425</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA20><s1>374-379</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>4790</s2><s5>354000131749830060</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>34 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0388191</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Biomedicine & pharmacotherapy</s0></fA64><fA66 i1="01"><s0>FRA</s0></fA66><fC01 i1="01" l="ENG"><s0>The importance of antioxidants in maintaining homeostasis has long been accepted and includes antioxidant proteins such as, peroxire-doxin (Prx), superoxide dismutase and glutathione S transferases. Sulfiredoxin (Srx) is a recently identified antioxidant protein with a role in signaling through catalytic reduction ofoxidative modifications. It was first characterized for its regulation of Prx(s) through reduction of the conserved cysteine from sulfinic to sulfenic acid, thereby impacting the role of Prx in regulation of downstream transcription factors and kinase signaling pathways. Furthermore, the reduction of sulfinic to sulfenic acid prevents further oxidation of the conserved cysteine residue to sulfonic acid, the end result of which is degradation. Srx also has a role in the reduction of glutathionylation a post-translational, oxidative modification that occurs on numerous proteins and has been implicated in a wide variety of pathologies, including Parkinson's disease. The regulation of glutathionylation/deglutathionylation (or thiol switch) has been likened to phosphorylation/dephosphorylation, another post-translational modification involved in the regulation of signaling pathways. Unlike, the reduction of Prx over-oxidation, Srx-dependent deglutathionylation appears to be non-specific. Deglutathionylation of multiple proteins has been observed both in vitro and in vivo in response to oxidative and/or nitrosative stress. This review discusses Srx as a novel antioxidant, and focuses on its potential role in the regulation of glutathionylation/deglutathionylation pathways, that have been implicated in a growing number of disease states.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Traitement</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Treatment</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Glutathion</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Glutathione</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Glutatión</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Stress oxydatif</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Oxidative stress</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Estrés oxidativo</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Oxygène actif</s0><s4>INC</s4><s5>86</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Azote actif</s0><s4>INC</s4><s5>87</s5></fC03><fN21><s1>269</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000778 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000778 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:05-0388191
|texte= Sulfiredoxin : a potential therapeutic agent? : Antioxidants in the Prevention of Human Diseases
}}
| This area was generated with Dilib version V0.6.29. |  |